The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Read more on fda.gov
Following a prostate cancer diagnosis, patients are faced with a multitude of care options, the advisability of which is influenced by patient factors and by cancer severity or aggressiveness. The ability to categorize patients based on cancer aggressiveness is invaluable for facilitating care decisions.
Accordingly, these guidelines for the management of localized prostate cancer are structured first, to provide a clinical framework stratified by cancer severity (or risk group) to facilitate care decisions and second, to guide the specifics of implementing the selected management options.
In Scope: active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU) and focal therapy.
Out of Scope: Secondary or salvage treatment for localized prostate cancer that persists or recurs after primary definitive intervention, and primary treatment of locally advanced/metastatic disease.
Read more on www.auanet.org
Here is the latest issue of Prostate Cancer Communication. It is a publication from PAACT (Patient Advocates for Advanced Cancer Treatments). There are some good articles that may be of interest to you.
PAACT Newsletter Volume 33, Number 1 – Spring 2017
From PBS interview with Dr .Elisabeth Rosenthal. 6 Questions to ask your doctor.
Read more on PBS.org
A newly published study in the journal Urology (the “Gold Journal”) has suggested that — at least for patients with a PSA level between 4 and 10 ng/ml — PSA density may be better than PSA level in the determination of which of these patients need to go on to have a biopsy.
- PSA density was a much more accurate predictor of risk than PSA alone for all men with a PSA level of 4 ng/ml or higher.
- Among men with a PSA level of < 4 ng/ml, PSA density was no better than PSA at predicting actual prostate cancer (of any type or of clinical significance).
Read more on prostatecancerinfolink.net
The minimally invasive treatment uses steam to kill cells and shrink the prostate and can be used on a wider range of anatomies.
Early results in clinical practice on large prostates appear “promising” and a study on prostates up to 150 grams is expected to begin later this year.
Read more on Wall Street Journal
Genomic testing is done on cancerous tissue taken from the prostate in order to provide information about how your prostate cancer might behave. By looking at the genetic makeup of the cancer, these tests may help predict whether your prostate cancer grows slowly or aggressively.
Genomic testing can be performed on both biopsy tissue and on tissue from an entire prostate following a prostatectomy.
Read more on Zero
Men diagnosed with prostate cancer are faced with an array of prostate treatment options. Proton beam therapy—a form of external beam radiation therapy—is the latest choice now available in the United States. But it’s a controversial option as well, with some critics suggesting that its popularity may be driven by advertising rather than by sound scientific evidence of benefit over other therapies.
Read more on healthafter50.com